Search results
Results from the WOW.Com Content Network
Hepatic artery embolization, also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. The embolization therapy can reduce the size of the tumor, and decrease the tumor's impact such its hormone production, effectively decreasing symptoms.
Transarterial bland embolization (TAE, also known as HAE) is a catheter-based tumor treatment of the liver.In this procedure, embolizing agents (e.g., polyvinyl alcohol, gelfoam, acrylic copolymer gelatin particles, embospheres) can be delivered through the tumor's feeding artery in order to completely occlude the tumor's blood supply.
Hence, arterial treatment targets the tumor while normal liver is relatively spared. Embolization induces ischemic necrosis of tumor causing a failure of the transmembrane pump, resulting in a greater absorption of cytotoxic agents by the tumor cells. Tissue concentration of agents within the tumor is greater than 40 times that of the ...
Consultant interventional radiologist Dr Brian Stedman said his team had performed 300 procedures in 100 patients whose form of eye cancer known as ocular melanoma had spread to the liver, called ...
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
Portal vein embolization (PVE) is a preoperative procedure performed in interventional radiology to initiate hypertrophy of the anticipated future liver remnant a couple weeks prior to a major liver resection procedure. The procedure involves injecting the right or left portal vein with embolic material to occlude portal blood flow.
Low-risk patients with unresectable liver cancer appear to gain control over their malignancies for at least 2 years when treated with TheraSphere. They survived a median of 800 days compared with a median of 258 days for high risk patients (P <.0001) in a study of 140 patients (106 male). The patients underwent 238 administrations of the ...
Nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors ...